Robert F. Kennedy Jr.'s Vaccine Shake-Up Sparks Coast-To-Coast Divide: West Coast Creates Health Alliance, Florida Rolls Back Requirements California, Oregon and Washington form regional vaccine alliance to counter federal guidance under Robert F. Kennedy Jr. as Florida eliminates state mandates.
Florida Chooses 'Medical Freedom' As State Plans To End Vaccine Mandates, Even For Schools: Experts Warn Of 'Major Disaster' Florida plans to end all statewide vaccine mandates, even those required for school attendance, framing the move as a defense of individual liberties, which has since received pushback from public health experts.
Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday? Wave Life Sciences shares early WVE-006 trial results in alpha-1 antitrypsin deficiency, reporting durable protein production and favorable safety.
Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds Upstream Bio's Phase 2 trial of verekitug in chronic rhinosinusitis met all endpoints, showing reduced nasal polyps, congestion, and need for surgery.
Bernie Sanders Demands Health Secretary RFK Jr.'s Resignation As CDC Leadership Crisis Deepens Senator Bernie Sanders called for HHS Secretary RFK Jr.'s resignation over his anti-vaccine policies, ousting of CDC Director Susan Monarez.
Elizabeth Warren Slams Trump's CDC Purge: Calls Out RFK Jr's Statements On Measles Vaccines — 'These Fools Can't Be Trusted With Your Health' Sen. Elizabeth Warren (D-Mass.) is sounding the alarm on President Donald Trump's attempts at overhauling leadership at the Centers for Disease Control and Prevention, warning of risks to public health.
Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.
GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.
GSK Expects Full-Year Earnings At Top End Of Guidance: CEO Says ‘Confident In Our Long-Term Outlooks’ GSK now expects turnover growth to be toward the top end of 3% to 5% and core earnings per share growth to be closer to 8% at constant exchange rate.
After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion.
GSK's Blood Cancer Drug Review Extended As FDA Seeks More Data FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.
GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of July 23 PDUFA decision.
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.
